February 23, 2024Open Access

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia

Key Points

Key points are not available for this paper at this time.

Abstract

Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and adherence. The report highlights the risk for bedaquiline resistance development and the need for rapid drug-resistance testing.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Günther et al. (Fri,) studied this question.

synapsesocial.com/papers/68e77c94b6db6435876f1087 https://doi.org/https://doi.org/10.3201/eid3003.240134

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Evidence-based Definition for Extensively Drug-Resistant Tuberculosis2021 · 37 citations
2Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study2023 · 75 citations
3Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs2018 · 90 citations
4Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB2023 · 22 citations
5Pretomanid-resistant tuberculosis2023 · 24 citations

KI fragen

Bookmark

View Full Paper